SOURCE: International Stem Cell Corporation

International Stem Cell Corporation

August 28, 2014 08:30 ET

International Stem Cell Corporation to Present at Two Upcoming Investment Conferences

CARLSBAD, CA--(Marketwired - August 28, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw will present a corporate overview of ISCO and its subsidiaries at two upcoming investment conferences.

Rodman and Renshaw 16th Annual Global Investment Conference:

Date: Wednesday, September 10, 2014
Time: 11:40 a.m. ET
Location: New York Palace Hotel, New York, NY
Room: Kennedy I

Conference details: http://www.meetmax.com//sched/event_23003/~public/conference_home.html?event_id=23003

AEGIS CAPITAL Corp. 2014 Healthcare and Technology Conference:
Date: Thursday, September 11, 2014
Time: 10:45 a.m. PT
Location: The Encore at Wynn, Las Vegas, NV

Conference details: http://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932

Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell.

Contact Information

  • Contacts:

    International Stem Cell Corporation
    Dr. Simon Craw
    Executive Vice President
    Phone: 760-940-6383
    Email: ir@intlstemcell.com